J&J | JNJ - Interest Expense On Debt



J&J reported $128M in Interest Expense on Debt for its fiscal quarter ending in March of 2025.


Interest Expense On Debt Change Date
AbbVie USD 700M 90M Mar/2025
Abbott USD 50M 1000K Jun/2025
Amgen USD 694M 29M Jun/2025
AstraZeneca 303M 126M Jun/2025
Baxter International USD 81M 19M Mar/2025
Bayer 495M 89M Jun/2025
Becton, Dickinson and Co. USD 152M 1000K Jun/2025
Biogen USD 72.6M 12.6M Jun/2025
Boston Scientific USD 90M 8M Jun/2025
Bristol-Myers Squibb USD 485M 9M Jun/2025
CONMED USD 7.82M 462K Jun/2025
Cooper Companies USD 25.4M 1.2M Jul/2025
Dexcom USD 4.7M 0 Jun/2025
Edwards Lifesciences 15.5M 1000K Jun/2024
Eli Lilly USD 249M 5.3M Jun/2025
Gilead Sciences USD 254M 6M Jun/2025
GlaxoSmithKline 184M 22M Jun/2025
Globus Medical 4K 9K Jun/2025
Hologic USD 28.9M 200K Jun/2025
Insulet USD 9.5M 8.3M Jun/2025
Integra LifeSciences USD 21.04M 2.23M Jun/2025
Intuitive Surgical 74.9M 18.8M Dec/2024
J&J USD 128M 9M Mar/2025
Medtronic USD 176M 2M Jul/2025
Merck USD 305M 8M Jun/2025
Merit Medical Systems USD 6.78M 207K Jun/2025
Novartis USD 289M 19M Jun/2025
Pfizer USD 654M 0 Jun/2025
Regeneron Pharmaceuticals USD 3.6M 5.1M Jun/2025
Roche Holding CHF 311.5M 1000K Dec/2024
Sanofi 148M 65M Jun/2025
Stryker 42M 11M Sep/2024
Tandem Diabetes Care USD 1.9M 43K Jun/2025
Teva Pharmaceutical Industries USD 252M 40M Jun/2025
Vertex Pharmaceuticals USD 3.7M 900K Jun/2025
Zimmer Biomet Holdings USD 79.3M 17.4M Jun/2025
Zoetis USD 53M 1000K Jun/2025